Cell and Gene Therapy Market Witnesses Rising Investments in Advanced Therapeutics

Cell and Gene Therapy Market

The global cell and gene therapy market size was valued at USD 27.38 billion in 2025 and is projected to grow from USD 33.85 billion in 2026 to USD 184.60 billion by 2034, registering a CAGR of 23.62% during the forecast period (2026–2034). The market is experiencing rapid growth due to advancements in genetic engineering, increasing investments in biotechnology research, and the growing use of advanced therapies for treating cancer, rare genetic disorders, and chronic diseases. The development of personalized treatment approaches and improvements in cell processing technologies are also supporting the expansion of the industry.

Cell and gene therapies represent an important advancement in modern medicine because they target the underlying causes of diseases rather than focusing only on symptom management. Cell therapy involves introducing, modifying, or replacing cells to restore normal biological functions, while gene therapy uses genetic material to correct, replace, or modify defective genes. These approaches are creating new treatment possibilities for conditions that have limited conventional treatment options.

For detailed market insights, growth forecasts, and competitive analysis, visit: https://straitsresearch.com/report/cell-and-gene-therapy-market

Market Drivers

Increasing Prevalence of Cancer and Genetic Disorders Drives Market Growth

The growing prevalence of cancer and inherited genetic disorders is increasing the need for advanced treatment approaches. Conventional treatments such as chemotherapy and long-term medication may not provide sufficient outcomes for certain complex conditions. Cell and gene therapies offer targeted treatment possibilities by modifying cellular functions or addressing genetic abnormalities.

CAR-T cell therapies, for example, use modified immune cells to recognize and attack cancer cells. Similarly, gene replacement and gene-editing approaches are being developed to address inherited disorders. The expanding clinical use of these technologies is supporting investments in research, development, and commercialization.

Advancements in Genetic Engineering and Biotechnology

Technological improvements in genetic engineering are supporting the development of more precise and effective therapies. Tools such as CRISPR-based gene editing, viral vectors, and advanced cell modification techniques allow researchers to develop treatments targeting specific biological mechanisms.

Improvements in vector design, cell isolation, manufacturing processes, and quality control are also helping developers address technical limitations. These advancements are strengthening the potential applications of cell and gene therapies across oncology, hematology, neurology, and rare diseases.

Rising Investments in Research and Development

Biopharmaceutical companies, research institutions, and biotechnology organizations are increasing investments in advanced therapeutic development. Funding for clinical trials, manufacturing facilities, and research partnerships is supporting the transition of experimental treatments into commercial products.

Collaborations between biotechnology companies and pharmaceutical manufacturers are also improving access to specialized technologies, research capabilities, and manufacturing infrastructure.

Market Challenges

High Treatment and Manufacturing Costs

The high cost of developing and administering cell and gene therapies remains a major challenge. These treatments often require specialized manufacturing facilities, advanced laboratory equipment, highly trained personnel, and strict quality-control procedures. Personalized therapies may also require patient-specific cell collection, modification, testing, and reinfusion.

These requirements increase production expenses and can limit treatment accessibility, particularly in healthcare systems with restricted reimbursement budgets.

Complex Regulatory and Approval Requirements

Cell and gene therapies require extensive clinical evaluation because of their complex biological characteristics and potential long-term effects. Regulatory authorities assess product safety, manufacturing consistency, treatment effectiveness, and patient monitoring requirements.

Differences in regulatory frameworks across countries can also complicate product approvals and commercialization. Companies must invest considerable resources in clinical trials, documentation, and compliance procedures.

Manufacturing and Supply Chain Limitations

The production of advanced therapies requires specialized infrastructure and controlled manufacturing environments. Challenges related to cell collection, transportation, storage, contamination prevention, and product consistency can affect treatment availability. Limited manufacturing capacity may also delay clinical development and commercial distribution.

Market Segmentation

The cell and gene therapy market is segmented by therapy type, application, end user, and delivery vector. These categories represent the different treatment technologies, medical conditions, and healthcare settings involved in the development and administration of advanced therapies.

By Therapy Type

Based on therapy type, the market is divided into cell therapy and gene therapy. Cell therapy involves introducing living cells into the body to repair damaged tissues, restore cellular functions, or support immune responses. CAR-T cell therapy, stem cell therapy, and other immune-cell-based treatments are important areas of development. These therapies are increasingly used in oncology and regenerative medicine.

Gene therapy focuses on modifying or replacing defective genetic material to treat or prevent diseases. Viral and non-viral delivery systems help transfer therapeutic genetic material into target cells. Gene editing and gene replacement technologies are expanding treatment possibilities for inherited disorders and other complex conditions.

By Application

Based on application, the market covers oncology, genetic disorders, neurological disorders, cardiovascular diseases, and other medical conditions. Oncology represents an important application area because cell-based immunotherapies are being developed to target specific cancer cells. CAR-T treatments and other engineered cellular approaches are expanding therapeutic options for certain blood cancers and solid tumors.

Genetic disorders are another major application area, with gene-based treatments designed to address inherited mutations. Research involving conditions such as sickle cell disease, hemophilia, and certain inherited neurological disorders is supporting the development of targeted therapies. Other applications include autoimmune conditions, cardiovascular diseases, and tissue-related disorders.

By End User

Based on end user, the market includes hospitals, specialty clinics, cancer treatment centers, research institutes, and other healthcare facilities. Hospitals play an important role because many advanced therapies require specialized medical teams, patient monitoring, and coordinated treatment procedures.

Specialty clinics and cancer treatment centers support the administration of complex cellular therapies, particularly treatments requiring specialized oncology services. Research institutes and biotechnology organizations contribute through clinical investigations, technology development, and early-stage therapeutic research.

By Delivery Vector

The market is divided into viral and non-viral delivery systems. Viral vectors, including adeno-associated viruses, lentiviruses, and retroviruses, are widely used to deliver therapeutic genetic material into target cells. Their ability to support efficient gene transfer makes them important in the development of several gene therapies.

Non-viral delivery systems include lipid nanoparticles, electroporation, and other physical or chemical delivery technologies. These approaches are attracting attention because they can offer alternative manufacturing and delivery strategies while supporting the development of different genetic modification techniques.

Regional Insights

North America holds a prominent position in the cell and gene therapy market due to its established biotechnology industry, advanced healthcare infrastructure, and strong clinical research ecosystem. The United States plays a major role through biotechnology investments, pharmaceutical research, and regulatory support for advanced therapies. The presence of specialized treatment centers and established biopharmaceutical manufacturers further supports regional development.

Asia-Pacific is expected to offer significant growth opportunities due to expanding biotechnology capabilities, rising healthcare investments, and increasing clinical research activity. China, Japan, South Korea, and India are strengthening their life sciences sectors through research funding, manufacturing development, and collaborations between healthcare institutions and biotechnology companies. The region's growing patient population and expanding access to specialized healthcare services also support market development.

Key Players Analysis

The cell and gene therapy market is moderately fragmented, with competition involving established pharmaceutical companies, biotechnology developers, and specialized advanced therapy manufacturers. Leading companies are focusing on research and development, clinical pipeline expansion, strategic collaborations, and manufacturing improvements to strengthen their market positions. Product innovation in CAR-T therapies, gene editing, and regenerative medicine remains an important competitive strategy.

• Novartis

• Gilead Sciences

• Bristol Myers Squibb

• Vertex Pharmaceuticals

• Bluebird Bio

• Sarepta Therapeutics

• Krystal Biotech

• Rocket Pharmaceuticals

• CRISPR Therapeutics

• Intellia Therapeutics

• Editas Medicine

• Beam Therapeutics

• Legend Biotech

• Cellectis

• Autolus Therapeutics

• Mesoblast

• Fate Therapeutics

• Bayer AG

Conclusion

The cell and gene therapy market is expected to experience substantial growth through 2034, supported by advancements in genetic engineering, increasing clinical research, and the growing need for targeted treatments for cancer and rare genetic disorders. Cell-based immunotherapies and gene-editing technologies are creating new opportunities for pharmaceutical and biotechnology companies. North America maintains a leading regional position, while Asia-Pacific offers significant growth potential through expanding biotechnology infrastructure and research investments. Continued improvements in manufacturing capabilities, treatment accessibility, and regulatory frameworks will play an important role in shaping the industry's development. With a projected CAGR of 23.62% during 2026–2034, the market is positioned for significant expansion over the forecast period.

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: [email protected]

Tel: +1 646 905 0080 (U.S.)

Tel: +44 203 695 0070 (U.K.)